1. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients
- Author
-
Alicia Olarte, Lucia Ceniceros, Christian D. Rolfo, Jairo Legaspi, M. Moreno, Eduardo Castanon, Germán Valtueña, Ignacio Gil-Bazo, and José Javier Aristu
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Stage I Non-Small Cell Lung Cancer ,Radiosurgery ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Therapeutic approach ,0302 clinical medicine ,Quality of life ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Lung cancer ,Lung ,business.industry ,General Medicine ,medicine.disease ,respiratory tract diseases ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Non small lung cancer ,Female ,Cell cancer ,Radiology ,Human medicine ,business ,Stereotactic body radiotherapy - Abstract
Lung cancer is the most frequent neoplasm in humans. Surgery is considered the best therapeutic approach for stage I non-small lung cell cancer (NSCLC). However, a remarkable amount of patients are considered as inoperable. Stereotactic body radiotherapy (SBRT) has risen as an option for those patients, rendering excellent results in quality of life and survival. We analyzed clinical studies published between 2002 and 2015 which included SBRT as a treatment modality. Our own clinical series was analyzed as well. The patterns of failure following SBRT were investigated, together with the outcomes and the toxicity observed. SBRT has proven to maintain an excellent local control. The analysis showed the tumor size and the histology as determinant factors for the response to treatment. According to the published evidence as well as our own experience, SBRT is a safe and feasible approach for early NSCLC. Its results may be comparable with surgery treatment.
- Published
- 2016